Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

A streamlined, automated process helps scientists coordinate site-ready production-level whole genome sequencing results.

Illumina, Inc. ILMN recently announced the release of Illumina Connected Multiomics, a cloud-based research software platform to analyze and visualize multiomic and multimodal biological data at scale ...

During the meeting, Steve Barnard, PhD, Illumina’s CTO will provide new details about the company’s constellation mapped read technology. He will be joined by Niall Lennon, PhD, chair and CSO of Broad ...

A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely ...

Illumina, Inc. has announced that scientists at the Company have sequenced the genome of an anonymous African male (Yoruba from Ibadan, Nigeria), using the Genome Analyzer. Sequencing of this HapMap ...

The Chinese government took its economic sanctions against San Diego-based Illumina a step further Tuesday by banning the gene-sequencing company from importing its machines to the country. It’s part ...